Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study of Abuse-Deterrent Morphine, Egalet-001
22 janv. 2015 08h00 HE
|
Egalet Corporation
WAYNE, Pa., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced positive results from a Category 3 human abuse liability (HAL) study of Egalet-001, an...
Egalet Appoints Deanne F. Melloy as Chief Commercial Officer
09 janv. 2015 08h00 HE
|
Egalet Corporation
WAYNE, Pa., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the appointment of Deanne F. Melloy as chief commercial officer (CCO). Ms. Melloy will be...
Egalet Acquires/Licenses Two Innovative Approved Pain Products
08 janv. 2015 08h14 HE
|
Egalet Corporation
--Transactions transform Egalet into a commercial specialty pharmaceutical company paving the way for commercialization of late-stage pipeline of abuse-deterrent opioids --
-- Company has...
Egalet to Present at the Stifel 2014 Healthcare Conference on November 18
05 nov. 2014 08h30 HE
|
Egalet Corporation
WAYNE, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that Bob Radie, president and chief executive officer, is scheduled to present at the Stifel...
Egalet Announces Update on Clinical Development Plan for Abuse-Deterrent Morphine Egalet-001
23 sept. 2014 16h00 HE
|
Egalet Corporation
WAYNE, Pa., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) (Egalet) today announced an update to the clinical development plan for Egalet-001, an abuse-deterrent,...
Egalet Announces Issuance of U.S. Patents Covering Guardian(TM) Technology and Product Candidates
11 sept. 2014 08h00 HE
|
Egalet Corporation
WAYNE, Pa., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the issuance of patents by the U.S. Patent and Trademark Office (USPTO) covering Egalet's...
Egalet to Present Data from Abuse-Deterrence Studies at PAINWeek 2014 in Las Vegas
04 sept. 2014 08h30 HE
|
Egalet Corporation
LAS VEGAS, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") announces data presentations on Egalet-001, an abuse-deterrent, extended-release, oral morphine product...
Egalet Announces Successful End-of-Phase 2 Meeting With the FDA for Egalet-002
18 août 2014 08h00 HE
|
Egalet Corporation
WAYNE, Pa., Aug. 18, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the completion of a successful end-of-Phase 2 meeting with the U.S. Food and Drug...
Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001
06 août 2014 06h00 HE
|
Egalet Corporation
WAYNE, Penn., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that we have top-line results from two of the three bioequivalence (BE) studies of...
Egalet to Present at the Canaccord Genuity Growth Conference on August 13
30 juil. 2014 08h30 HE
|
Egalet Corporation
WAYNE, Pa., July 30, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that Bob Radie, president and chief executive officer, is scheduled to present at the...